PMV Pharmaceuticals (PMVP) to Release Quarterly Earnings on Thursday

Key Points

• PMV Pharmaceuticals is set to release its Q2 2025 earnings on August 14th, with analysts expecting a loss of ($0.39) per share.
• The stock has seen a 2.7% increase recently, opening at $1.52, and has a market cap of approximately $78.96 million.
• Insider activity has been notable, with CEO David Henry Mack selling 58,411 shares, reducing his ownership by 9.82%.

PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) is anticipated to release its Q2 2025 earnings data before the market opens on Thursday, August 14th. Analysts expect PMV Pharmaceuticals to post earnings of ($0.39) per share for the quarter.

PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) last posted its earnings results on Friday, May 9th. The company reported ($0.34) EPS for the quarter, beating analysts' consensus estimates of ($0.37) by $0.03. On average, analysts expect PMV Pharmaceuticals to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

PMV Pharmaceuticals Trading Up 2.7%

PMVP opened at $1.52 on Thursday. The stock's 50-day moving average price is $1.20 and its 200 day moving average price is $1.17. PMV Pharmaceuticals has a 12-month low of $0.81 and a 12-month high of $1.82. The firm has a market cap of $78.96 million, a price-to-earnings ratio of -1.29 and a beta of 1.52.

Insider Activity at PMV Pharmaceuticals

In other news, CEO David Henry Mack sold 58,411 shares of PMV Pharmaceuticals stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $1.06, for a total transaction of $61,915.66. Following the sale, the chief executive officer owned 536,133 shares in the company, valued at approximately $568,300.98. The trade was a 9.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Deepika Jalota sold 33,065 shares of the stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $1.06, for a total value of $35,048.90. Following the completion of the sale, the insider directly owned 89,959 shares of the company's stock, valued at $95,356.54. The trade was a 26.88% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 114,627 shares of company stock worth $121,505 over the last quarter. 7.57% of the stock is currently owned by insiders.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.